Navigation Links
Biomarkers: Technological and Commercial Outlook 2012-2022
Date:9/3/2012

NEW YORK, Sept. 3, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biomarkers: Technological and Commercial Outlook 2012-2022

http://www.reportlinker.com/p0578545/Biomarkers-Technological-and-Commercial-Outlook-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

Report Details

Biomarkers - discover market outlooks and industry trends

What are the prospects for biomarker research, products and services? Visiongain's report shows you potential revenues and other trends to 2022, discussing data, outlooks and opportunities.

Our new study analyses the commercial potential for biomarker products and services. You find projected revenues to 2022 at world market, submarket, leading scientific discipline, leading indication and national market level. 

Analysis of submarkets and scientific areas

You see world-level forecasting for the following submarkets:

• Biomarker development and technologies

• Biomarker diagnostics

• Biomarker services.

Also, you receive revenue forecasts to 2022 by scientific discipline:

• Genomics

• Proteomics

• Bioinformatics.

How will leading countries perform?

Our study gives revenue forecasts to 2022 for nine prominent national markets:

• US

• Japan

• France, Germany, UK, Spain and Italy (EU5 countries)

• China

• India.

Technological research in leading markets will drive worldwide growth in revenues for biomarker products and services from 2012 to 2022, our investigation shows.

You discover prospects for leading therapeutic sectors for biomarker diagnostics and research

Our report also analyses leading therapeutic market areas for biomarker applications. You receive revenue forecasts for three therapeutic submarkets to 2022:

• Cancer

• Cardiovascular disease

• CNS diseases.

What issues decide the future of the industry and market?

Our study helps you assess industry trends and market outlooks. You find discussions of many issues and developments:

• Intellectual property for biomarkers

• Regulatory guidance for biomarker validation and qualification

• Improvements to discovery instruments and tools

• Outsourcing biomarker discovery and development

• Collaboration between public institutions and the pharmaceutical industry

• Challenges in co-developing drugs and diagnostics.

Our work gives you multi-level business research and analysis with sales predictions. You see how that industry and market can perform to 2022.

Biomarker products and technologies: market growth and commercial prospects from 2012

Where is the biomarkers market heading? Overall revenues for biomarker products and services will rise from 2012-2022, our report forecasts. 

There is great demand for accurate, non-invasive diagnostics. Development of tests for disease diagnosis, prognosis and treatment responses gives opportunities for companies seeking to enter the biomarkers market. Our report shows you and explains.

What about developments in new areas of research? Epigenomics, metabolomics and microRNA hold promise as new sources of disease biomarkers, our analyses show.

How can companies harness the potential that biomarkers offer in drug discovery and development?

Discover profiles for prominent companies

Our report profiles leading companies operating in each market sector, assessing the technologies, products and services of twelve CROs, seven technology providers and seven diagnostics manufacturers, including these:

• Covance

• Charles River Laboratories

• Caprion Proteomics

• Affymetrix

• AB SCIEX

• Life Technologies

• Quest Diagnostics

• Myriad Genetics

• Genomic Health.

Our study also covers the role of pharmaceutical companies in the biomarkers market. You see recent developments for eight leading pharma companies.

Market forecasts, R&D trends, company and segment analyses and discussions of industry prospects

In visiongain's study you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), company profiles and commercial developments. You receive 56 tables, 53 charts and two research interviews.

Nine ways Biomarkers: Technological and Commercial Outlook 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:

• Find potential revenues to 2022 for the overall world market and submarkets

• Discover forecasted revenue trends by therapeutic sector to 2022

• Find projected biomarker revenues for 3 leading scientific disciplines to 2022

• Assess 26 prominent companies, discovering activities and outlooks

• Analyse market prospects for 8 leading pharma companies adopting biomarkers in drug discovery and development

• See market forecasting to 2022 for the US, Japan, 5 leading EU countries, Chinaand India

• Review technological, regulatory and commercial developments, assessing trends and prospects

• Find out what will stimulate and restrain the industry and market from 2012

• View opinions from our survey, seeing interviews with market participants.

There you find quantitative and qualitative analyses with independent predictions. You receive information unique to our report, helping you stay informed on business intelligence.

Gain research and analysis on the biomarkers market now

Our study is for everybody needing biomarker industry and market analyses. You find data, predictions and answers there. Please order that report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6 

Table of Contents

1. Executive Summary

1.1 Biomarkers: World Market Overview

1.2 Chapter Breakdown

1.3 Research and Analysis Methods

1.4 Market Definition 2012

2. An Introduction to the Concept and Use of Biomarkers

2.1 Definition of a Biomarker

2.1.1 A Brief History of Biomarkers

2.1.2 The Importance of Biomarkers

2.2 Biomarker Discovery and Validation

2.3 Uses of Biomarkers

2.3.1 Assessing Drug Efficacy

2.3.2 Assessing Drug Safety

2.3.3 Companion Diagnostics

2.3.3.1 CLIA vs. FDA Approval

2.3.4 Therapeutic Importance of Biomarkers

2.3.5 Imaging Biomarkers

2.3.5.1 Imaging Biomarkers in Clinical Trials

2.4 Biomarkers and Personalised Medicine

2.5 Biomarker Discovery

2.5.1 Genomics

2.5.1.1 Pharmacogenomics

2.5.2 Proteomics

2.5.3 Metabolomics

3. The World Biomarkers Market 2012-2022

3.1 The World Biomarkers Market 2011

3.1.1 The Biomarkers Market by Sector 2011

3.1.2 The Biomarkers Market by Discipline 2011

3.2 The Biomarkers Market: Overall Revenue Forecast 2012-2022

3.3 The Biomarker Development and Technologies Submarket 2011

3.3.1 The Biomarker Development and Technologies Submarket: Revenue Forecast 2012-2022

3.4 The Biomarker Diagnostics Submarket 2011

3.4.1 The Biomarker Diagnostics Submarket: Revenue Forecast 2012-2022

3.5 The Biomarker Services Submarket 2011

3.5.1 The Biomarker Services Submarket: Revenue Forecast 2012-2022

3.6 Growth in Key Biomarker Disciplines 2012-2022

3.6.1 The Genomics Submarket: Revenue Forecast 2012-2022

3.6.1.1 Next Generation Sequencing to Drive Growth

3.6.2 The Proteomics Submarket: Revenue Forecast 2012-2022

3.6.3 The Bioinformatics Submarket: Revenue Forecast 2012-2022

4. Leading Indications for Biomarker Discovery and Development 2012-2022

4.1 The World Biomarkers Market by Indication 2011

4.2 The World Biomarkers Market by Indication 2012-2022

4.3 Cancer Biomarker Submarket 2012-2022

4.3.1 A Brief History of Cancer Biomarker Research

4.3.2 The State of Cancer Biomarker Research 2011

4.3.2.1 Cancer Genome Atlas

4.3.3 Many Cancer Diagnostics Are Reaching the Market

4.3.4 Opportunities and Challenges for Cancer Biomarkers

4.3.4.1 Prostate Cancer

4.3.4.2 Lung Cancer

4.3.5 Cancer Biomarker Submarket: Revenue Forecast 2012-2022

4.4 Cardiovascular Disease Biomarker Submarket 2012-2022

4.4.1 A Brief History of Cardiovascular Biomarker Research

4.4.2 The State of Cardiovascular Biomarker Research 2011

4.4.3 Cardiovascular Disease Diagnostics

4.4.4 The Future of Cardiovascular Biomarker Research

4.4.5 Cardiovascular Disease Biomarker Submarket: Revenue Forecast 2012-2022

4.5 CNS Diseases Biomarker Submarket 2012-2022

4.5.1 The State of CNS Disease Biomarker Research 2011

4.5.2 Biomarker-Based Diagnostics for CNS Diseases

4.5.2.1 DiaGenic

4.5.3 Neuroimaging Biomarkers

4.5.4 CSF Biomarkers

4.5.5 Alzheimer's Disease

4.5.6 Multiple Sclerosis

4.5.7 Parkinson's Disease

4.5.8 CNS Diseases Biomarker Submarket: Revenue Forecast 2012-2022

5. Leading National Biomarker Markets 2012-2022

5.1 The Biomarkers Market: Regional Breakdown 2011

5.2 The Biomarkers Market: Regional Forecast 2012-2022

5.3 The US

5.3.1 The US: Biomarker Revenues 2012-2022

5.4 Leading EU Markets

5.4.1 Increased Funding for Biomarker Research in the UK

5.4.2 Leading EU Markets: Biomarker Revenues 2012-2022

5.5 Japan

5.5.1 Japan: Biomarker Revenues 2012-2022

5.6 China

5.6.1 Companies Entering the Chinese Market

5.6.2 LightArray Biotech

5.6.3 China: Biomarker Revenues 2012-2022

5.7 India

5.7.1 India: Biomarker Revenues 2012-2022

6. Biomarker Industry Trends 2012-2022

6.1 Strengths and Weaknesses in the Biomarkers Market 2011

6.2 Opportunities and Threats in the Biomarkers Market 2012-2022

6.3 Biomarkers Market: STEP Analysis

6.4 Social Factors

6.4.1 Patient Stratification

6.4.2 Biomarker Hype

6.4.3 Emphasis on Oncology

6.5 Technological Factors

6.5.1 Decreasing Size, Increasing Sensitivity

6.5.1.1 ABT Molecular Imaging

6.5.2 Data Storage

6.6 Economic Factors

6.6.1 Biomarkers: Cutting the Cost of Drug Development

6.6.1.1 Toxicity Biomarkers

6.6.2 The Cost of Technology

6.6.3 Outsourcing Biomarker Discovery and Development

6.7 Political Factors

6.7.1 Public-Private Partnerships

6.7.2 Improving Regulatory Guidelines

6.7.3 Biomarker Intellectual Property

6.8 Challenges in Developing Biomarkers

6.9 Combining Drug and Diagnostic Development

6.10 MicroRNA Biomarkers

6.11 Big Pharma and Biomarkers

6.11.1 Pfizer

6.11.2 Novartis

6.11.3 Merck & Co.

6.11.4 Sanofi

6.11.5 Roche

6.11.5.1 Roche Diagnostics

6.11.5.2 Ventana Medical Systems

6.11.5.3 Roche 454 Life Sciences

6.11.6 GSK

6.11.7 AstraZeneca

6.11.8 Abbott Laboratories/Abbott Molecular

7. Companies Participating in the Biomarkers Market 2012

7.1 Biomarker Service Providers

7.1.1 Global CROs and Biomarkers

7.1.1.1 Not All Global CROs Are Investing in Biomarkers

7.1.2 Quintiles

7.1.3 Covance

7.1.4 Parexel

7.1.5 Charles River Laboratories

7.1.6 ICON

7.1.7 WuXi AppTec

7.1.8 Caprion Proteomics

7.1.9 Proteome Sciences

7.1.10 Pacific Biomarkers

7.1.11 Oxford Gene Technology

7.1.12 NextGen Sciences

7.2 Biomarker Technology Providers

7.2.1 Affymetrix

7.2.1.1 QuantiGene

7.2.2 Agilent

7.2.2.1 Agilent and Diagnostics

7.2.3 AB SCIEX

7.2.4 QIAGEN

7.2.5 Life Technologies

7.2.6 Axela

7.2.7 Thermo Fisher Scientific

7.2.7.1 Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center

7.3 Biomarker Diagnostic Developers

7.3.1 Quest Diagnostics

7.3.2 Myriad Genetics

7.3.2.1 Pipeline

7.3.2.2 Myriad RBM

7.3.3 Genomic Health

7.3.4 Critical Diagnostics

7.3.5 BG Medicine

7.3.6 Epigenomics

7.3.6.1 Diagnostic Product Portfolio

7.3.7 MDxHealth

8. Opinions from Our Survey: Research Interviews

8.1 Dr Dan Chelsky, CSO, Caprion Proteomics

8.1.1 The Advantages to Outsourcing in the Biomarker Industry

8.1.2 Biomarkers and Bioinformatics

8.1.3 Caprion's Proteomics Services

8.1.4 Future Opportunities in Proteomics

8.1.5 Therapeutic Focus of Biomarker Research

8.1.6 Alliances in Biomarker Services

8.1.7 Increasing Interest from the Pharmaceutical Industry

8.1.8 Proteomics and Diagnostics

8.2 Dr James Snider, President, Critical Diagnostics

8.2.1 Development of Biomarkers and Diagnostics

8.2.1.1 The Cost of Development

8.2.2 Growth in Cardiology Biomarkers and Diagnostics

8.2.3 Critical Diagnostics' Presage ST2 Assay

8.2.4 The Importance of the US Market

8.2.5 Companies Competing in the Market

8.2.6 Opportunities in Cardiac Biomarkers

9. Conclusions

9.1 State of the World Biomarkers Market in 2011

9.2 Growth in the World Biomarkers Market 2012-2022

9.2.1 Dominance of Leading Western Markets

9.3 The Use of Biomarkers in Drug Discovery and Development

9.4 Demand for New Diagnostics

List of Tables

Table 1.1 Currency Exchange Rates, 2011

Table 2.1 Selected Drugs with Pharmacogenomic Biomarkers Listed on their Labels, 2012

Table 2.2 Selected Clinically-Relevant Cancer Biomarkers, 2012

Table 2.3 Technologies and Platforms for Biomarker Research, 2012

Table 3.1 World Biomarkers Market by Sector, 2011

Table 3.2 World Biomarkers Market by Discipline, 2011

Table 3.3 World Biomarkers Market: Overall Market and Revenue Forecasts by Sector, 2011-2022

Table 3.4 Biomarker Sector Submarket Shares, 2011-2022

Table 3.5 Biomarker Development and Technologies Submarket: Revenue Forecast, 2011-2022

Table 3.6 Biomarker Diagnostics Submarket: Revenue Forecast, 2011-2022

Table 3.7 Biomarker Services Submarket: Revenue Forecast, 2011-2022

Table 3.8 Biomarker Discipline Submarket Shares, 2011-2022

Table 3.9 Genomics Submarket: Revenue Forecast, 2011-2022

Table 3.10 Selected Producers of Single-Molecule Sequencing Technologies, 2012

Table 3.11 Proteomics Submarket: Revenue Forecast, 2011-2022

Table 3.12 Bioinformatics Submarket: Revenue Forecast, 2011-2022

Table 4.1 World Biomarkers Market by Indication, 2011

Table 4.2 Biomarker Indication Submarket Shares, 2011-2022

Table 4.3 Selected Marketed Biomarker-Based Cancer Diagnostics, 2012

Table 4.4 Selected ALK Inhibitors in Development for Lung Cancer, 2012

Table 4.5 Cancer Submarket: Revenue Forecast, 2011-2022

Table 4.6 Cardiovascular Disease Submarket: Revenue Forecast, 2011-2022

Table 4.7 CNS Diseases Submarket: Revenue Forecast, 2011-2022

Table 5.1 Biomarkers: Market Shares by Country, 2011

Table 5.2 World Biomarkers Market: Revenue Forecasts by Country, 2011-2022

Table 5.3 National Biomarker Submarket Shares, 2011-2022

Table 5.4 US Submarket: Revenue Forecast, 2011-2022

Table 5.5 Top Five EU Submarkets: Revenue Forecasts, 2011-2022

Table 5.6 Japanese Submarket: Revenue Forecast, 2011-2022

Table 5.7 Chinese Submarket: Revenue Forecast, 2011-2022

Table 5.8 Indian Submarket: Revenue Forecast, 2011-2022

Table 6.1 World Biomarkers Market: Strengths and Weaknesses, 2011-2012

Table 6.2 World Biomarkers Market: Opportunities and Threats, 2012-2022

Table 6.3 World Biomarkers Market: STEP Analysis, 2012-2022

Table 6.4 Cancer Deaths by Tumour Type, 2008

Table 6.5 Selected Cancer Therapies Approved With a Biomarker, 2011

Table 6.6 PSTC Biomarkers in Development, 2012

Table 6.7 Average Cost of Sequencing the Human Genome 2000-2011

Table 6.8 IMI-Funded Biomarker Projects, 2009-2012

Table 6.9 Drug Discovery Outsourcing: Overall Market and Subsector Forecast, 2011, 2016 & 2022

Table 7.1 ICON: Frequently Requested Laboratory Biomarkers, 2012

Table 7.2 Proteome Sciences: Revenue, 2010-2011

Table 7.3 NextGen Group: Revenue by Region, 2011

Table 7.4 Affymetrix: Revenue by Division, 2009-2011

Table 7.5 Myriad Genetics: Biomarker Product Portfolio, 2012

Table 7.6 Myriad Genetics: Revenue by Product, 2010-2011

Table 7.7 Myriad Genetics: Diagnostic Pipeline, 2012

Table 7.8 Genomic Health: Revenue by Division, 2009-2011

Table 7.9 BG Medicine: Revenue by Division, 2009-2011

Table 7.10 Epigenomics: Revenue by Half-Year, 2010-2011

Table 7.11 MDxHealth: Pipeline, 2012

Table 7.12 MDxHealth: Revenue by Source, 2009-2011

Table 9.1 World Biomarkers Market: Revenues by Sector, 2011, 2016 and 2022

Table 9.2 World Biomarkers Market: Revenues by Discipline, 2011, 2016 and 2022

Table 9.3 World Biomarkers Market: Revenues by Disease, 2011, 2016 and 2022

Table 9.4 World Biomarkers Market: Revenues by Country, 2011, 2016 and 2022

List of Figures

Figure 2.1 Definitions of a Biomarker, 2012

Figure 2.2 The Biomarker Discovery and Validation Process, 2012

Figure 3.1 World Biomarkers Market by Sector, 2011

Figure 3.2 World Biomarkers Market by Discipline, 2011

Figure 3.3 World Biomarkers Market: Drivers and Restraints, 2012-2022

Figure 3.4 World Biomarkers Market: Overall Market Forecast, 2011-2022

Figure 3.5 Biomarkers: Market Shares by Sector, 2016

Figure 3.6 Biomarkers: Market Shares by Sector, 2022

Figure 3.7 Biomarker Development and Technologies Submarket: Drivers and Restraints, 2012-2022

Figure 3.8 Biomarker Development and Technologies Submarket: Revenue Forecast, 2011-2022

Figure 3.9 Biomarker Diagnostics Submarket: Revenue Forecast, 2011-2022

Figure 3.10 Biomarker Diagnostics Submarket: Drivers and Restraints, 2012-2022

Figure 3.11 Biomarker Services Submarket: Drivers and Restraints, 2012-2022

Figure 3.12 Biomarker Services Submarket: Revenue Forecast, 2011-2022

Figure 3.13 Biomarkers: Market Shares by Discipline, 2016

Figure 3.14 Biomarkers: Market Shares by Discipline, 2022

Figure 3.15 Genomics Submarket: Revenue Forecast, 2011-2022

Figure 3.16 Genomics Submarket: Drivers and Restraints. 2012-2022

Figure 3.17 Proteomics Submarket: Drivers and Restraints, 2012-2022

Figure 3.18 Proteomics Submarket: Revenue Forecast, 2011-2022

Figure 3.19 Bioinformatics Submarket: Revenue Forecast, 2011-2022

Figure 3.20 Bioinformatics Submarket: Drivers and Restraints, 2012-2022

Figure 4.1 World Biomarkers Market by Indication, 2011

Figure 4.2 Biomarkers: Market Shares by Indication, 2016

Figure 4.3 Biomarkers: Market Shares by Indication, 2022

Figure 4.4 Cancer Submarket: Revenue Forecast, 2011-2022

Figure 4.5 Cardiovascular Disease Submarket: Revenue Forecast, 2011-2022

Figure 4.6 CNS Diseases Submarket: Revenue Forecast, 2011-2022

Figure 5.1 Biomarkers: Market Shares by Country, 2011

Figure 5.2 Biomarkers: Market Shares by Country, 2016

Figure 5.3 Biomarkers: Market Shares by Country, 2022

Figure 5.4 US Submarket: Revenue Forecast, 2011-2022

Figure 5.5 Top Five EU Submarkets: Revenue Forecasts, 2011-2022

Figure 5.6 Japanese Submarket: Revenue Forecast, 2011-2022

Figure 5.7 Chinese Submarket: Revenue Forecast, 2011-2022

Figure 5.8 Indian Submarket: Revenue Forecast, 2011-2022

Figure 6.1 Cancer Deaths by Tumour Type, 2008

Figure 6.2 Average Cost of Sequencing the Human Genome 2000-2005

Figure 6.3 Average Cost of Sequencing the Human Genome 2006-2011

Figure 6.4 Drug Discovery Outsourcing: Overall Market and Subsector Forecasts, 2011, 2016 & 2022

Figure 7.1 ICON: Frequently Requested Laboratory Biomarkers, 2012

Figure 7.2 Proteome Sciences: Revenue, 2010-2011

Figure 7.3 NextGen Group: Revenue by Region, 2011

Figure 7.4 Affymetrix: Revenue by Division, 2009-2011

Figure 7.5 Myriad Genetics: Revenue by Product, 2010-2011

Figure 7.6 Genomic Health: Product Revenue, 2009-2011

Figure 7.7 BG Medicine: Product Revenue, 2009-2011

Figure 7.8 Epigenomics: Revenue by Half-Year, 2010-2011

Figure 7.9 MDxHealth: Revenue by Source, 2009-2011

Figure 9.1 World Biomarkers: Revenues Market by Sector, 2011, 2016 and 2022

Figure 9.2 World Biomarkers Market: Revenues by Discipline, 2011, 2016 and 2022

Figure 9.3 World Biomarkers Market: Revenues by Disease, 2011, 2016 and 2022

Figure 9.4 World Biomarkers Market: Revenues by Country, 2011, 2016 and 2022 

Companies Listed

454 Life Sciences (a subsidiary of Roche)

AB SCIEX (a subsidiary of Danaher)

Abbott Laboratories

Abbott Molecular

Abcodia

ABT Molecular Imaging

ACS Biomarker

Advanced Cell Diagnostics (ACD)

Advion Bioanalytical Labs (part of Quintiles)

Affymetrix

Agendia

Agilent

Alacris Theranostics

Alere

Amarantus BioSciences

Amgen

Applied Biosystems (part of Life Technologies)

Arctic Partners

ARIAD Pharmaceuticals

Arizona State University

Arrayit Diagnostics

ARUP Laboratories

Association for Molecular Pathology (AMP) [US]

Athena Diagnostics (a subsidiary of Quest Diagnostics)

Atherotech Diagnostics Lab

Aushon Biosystems

Axela

Bayer

Belfer Institute for Applied Cancer Science [US]

Berkeley HeartLab (a subsidiary of Quest Diagnostics)

BG Medicine

BGI (formerly Beijing Genomics Institute)

Biosoft

BRAHMS (part of Thermo Fisher Scientific)

Brigham and Women's Hospital

Bristol-Myers Squibb

British Heart Foundation [UK]

Broad Institute [US]

Cancer Research Technology

Cancer Research UK

Caprion Proteomics

Celera (part of Quest Diagnostics)

Celgene

Cell Signaling Technology

Celldex Therapeutics

Centers for Medicare and Medicaid Services (CMS) [US]

Cephalon (part of Teva)

Charles River Laboratories

Chronix Biomedical

Ciphergen Biosystems

Clarient

Cleveland HeartLab

Clinigene International

Commonwealth Scientific and Industrial Research Organisation (CSIRO) [Australia]

Comprehensive Biomarker Center (formerly febit)

Covance

Critical Diagnostics

Critical Path Institute (C-Path) [US]

Daiichi Sankyo

Dako (now part of Agilent)

Dana-Farber Cancer Institute [US]

Danaher

DiaGenic

Durin Technologies

DxS (now part of QIAGEN)

Eisai

EKO Diagnostic

Eli Lilly

Epigenomics

Epistem

EQT

ETH Zurich

European Commission

European Federation of Pharmaceutical Industries and Associations (EFPIA)

European Medicines Agency (EMA)

European Stroke Research Network for Hypothermia (Euro-HYP)

Evotec

Exact Sciences

Exiqon

Exonhit

Ezose Sciences (part of Shionogi)

Food and Drug Administration (FDA) [US]

Foundation Medicine

Fujirebio Diagnostics

GE Healthcare

Genetic Technologies

Geneva Bioinformatics (GeneBio)

Genomic Health

GenWay Biotech

Great Point Partners

GSK

Health Diagnostic Laboratory 

HealthLinx

Helicos BioSciences

Hewlett-Packard

Hirosaki University

HTG Molecular Diagnostics

Human Proteome Organisation (HUPO)

ICON

Insight Genetics

Integrated Diagnostics

International Cancer Genome Consortium (ICGC)

Ipsogen (a subsidiary of QIAGEN)

Isogen Life Science

Johnson & Johnson (J&J)

KU Leuven (University of Leuven)

LabCorp

Les entreprises du medicament (LEEM) [France]

Life Technologies

LightArray Biotech

Malmö University

Massachusetts General Hospital

Max Planck Institute for Molecular Genetics [Germany]

Mayo Clinic [US]

Mayo Collaborative Services 

MDxHealth

Medical Research Council [UK]

Memorial Sloan-Kettering Cancer Center [US]

Merck & Co.

Merck KGaA

Metabolon

Michael J Fox Foundation

Myriad Genetics

Myriad RBM (formerly Rules-Based Medicine, part of Myriad Genetics)

National Academy of Sciences (NAS) [US]

National Cancer Institute (NCI) [US]

National Health Service (NHS) [UK]

National Human Genome Research Institute (NHGRI) [US]

National Institute for Health and Clinical Excellence (NICE) [UK]

National Institute of Allergy and Infectious Diseases (NIAID) [US]

National Institute on Aging (NIA) [US]

National Jewish Health [US]

Nephromics

Newcastle University [UK]

NextGen Group

NextGen Sciences

NextGen Sciences Dx

Novartis

Novartis Molecular Diagnostics (part of Novartis)

NovioGendix

Oncoimmune

OpGen

OPKO Health

Orion Genomics

Oslo University Hospital

Oxford Cancer Biomarkers

Oxford Gene Technology (OGT)

Pacific Biomarkers

Pacific Biosciences

Panomics (now part of Affymetrix)

Parexel

Pathwork Diagnostics

Personal Genome Diagnostics

Pfizer

Pharmaceutical Research and Manufacturers of America (PhRMA)

Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]

PLUS Diagnostics

Power3 Medical Products

PPD

PPD Biomarker Discovery Services (now part of Caprion Proteomics)

Predictive Biosciences

Predictive Safety Testing Consortium (PSTC) [US]

Prometheus Laboratories

Proteome Sciences

QIAGEN

QLIDA Diagnostics

Quanterix

Quanticel Pharmaceuticals

Quest Diagnostics

Quintiles

Randox Laboratories

Roche

Roche Diagnostics (part of Roche)

SABiosciences (now part of QIAGEN)

Sandor Proteomics

Santaris Pharma

Seattle Genetics

Shanghai Jiao Tong University

Shionogi

Siemens

Siena Biotech

SMA Foundation [US]

Stanford University

State Food and Drug Administration (SFDA) [China]

Stemina Biomarker Discovery 

Sysmex

Takeda Pharmaceutical

Targeted Molecular Diagnostics (now part of Quintiles)

Technion-Israel Institute of Technology 

Technology Strategy Board (TSB) [UK]

Teva Pharmaceutical Industries

Thallion Pharmaceuticals

The Biomarkers Consortium

Thermo Fisher Scientific

Trans-Hit Biomarkers

Tufts Center for the Study of Drug Development

University of Alabama

University of Medicine and Dentistry of New Jersey (UMDNJ)

University of Oklahoma College of Pharmacy

University of Oslo

University of Turku

University of Washington

Ventana Medical Systems

Vertex Pharmaceuticals

Warnex

Wellcome Trust Sanger Institute [UK]

World Health Organization (WHO)

WuXi AppTec

Xcovery 

To order this report:

Genomics Industry: Biomarkers: Technological and Commercial Outlook 2012-2022

Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related biology technology :

1. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
2. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
3. Rosetta Genomics Expands Management Team, Laboratory Capacities and Commercial Operations
4. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
5. CANVUS Design Studio Specializes in Graphic Design and Commercials
6. Applied Genetics Initiates Commercial Operation
7. Lightning Brewery’s Craft Beer Old Tempestuous Ale Wins Best of Show at 2012 California State Fair Commercial Brewing Competition
8. Synteract Unveils New Branding at DIA 2012 to Support Enhanced Commercial Strategy
9. Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
10. UK company to demonstrate their commercially effective graphene production process
11. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from ... believe could be a new and helpful biomarker for malignant pleural mesothelioma. Surviving ... to read it now. , Biomarkers are components in the blood, tissue ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
Breaking Biology Technology:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
Breaking Biology News(10 mins):